Table 3.
Factors influencing KRAS testing in metastatic CRC patients
|
KRAS testing n = 190/290 (65.5%) |
Univariate analysis P-Value |
Multivariate analysis | |||
|---|---|---|---|---|---|
| Odds ratio | 95% CI | P-Value | |||
| Age (years) | < 0.0001 | < 0.0001 | |||
| > 75 | 42 / 107 (39.3%) | 1 | Ref | ||
| 60–75 | 97 / 126 (77.0%) | 4.72 | 2.54–8.77 | ||
| < 60 | 51 / 57 (89.5%) | 10.78 | 4.07–28.50 | ||
| Sex | 0.016 | 0.33 | |||
| Women | 82 / 140 (58.6%) | 1 | Ref | ||
| Men | 108 / 150 (72.0%) | 1.34 | 0.75–2.41 | ||
| Site of the primary tumour | 0.0011 | 0.006 | |||
| Rectum | 35 / 64 (54.7%) | 1 | Ref | ||
| Right colon | 51 / 90 (56.7%) | 1.44 | 0.67–3.07 | ||
| Left colon | 104 / 136 (76.5%) | 3.09 | 1.48–6.45 | ||
| Tumour grade (MD = 40) | 0.52 | ||||
| Well | 63 / 89 (70.8%) | ||||
| Moderate | 83 / 131 (63.4%) | ||||
| Poor | 20 / 30 (66.7%) | ||||
| Geographical area of primary treatment (MD = 2) | 0.0001 | 0.010 | |||
| Charente-Maritime | 42 / 87 (48.3%) | 1 | Ref | ||
| Charente | 32 / 53 (60.4%) | 1.99 | 0.89–4.46 | ||
| Deux-Sèvres | 37 / 45 (82.2%) | 4.64 | 1.77–12.18 | ||
| Vienne | 61 / 79 (77.2%) | 2.88 | 1.36–6.13 | ||
| Outside the region | 17 / 24 (70.8%) | 2.02 | 0.67–6.12 | ||
| Status of the center (MD = 2) | 0.026a | ||||
| Public Hospital | 60 / 83 (72.3%) | – | – | – | |
| Private hospital | 83 / 143 (58.0%) | ||||
| University hospital | 46 / 62 (74.2%) | ||||
95% CI 95% confidence interval, MD missing data, Ref reference
aNot retained in the final multivariate model